Overweight and obesity: The pathogenesis of cardiometabolic risk

Clinical Cornerstone

Volumn 9, Issue 4, 2009, Pages 30-42

  Bray, George A ^a   Clearfield, Michael B ^b   Fintel, Dan J ^c   Nelinson, Donald S ^d  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Touro University California   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d The Diabetes Consortium Inc Mountain Lakes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; FATTY ACID; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; RISK ASSESSMENT;

ADIPOKINES; ADIPOSITY; BODY SIZE; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; OBESITY; OBESITY, ABDOMINAL; OVERWEIGHT; RISK FACTORS; SEX FACTORS;

EID: 70349319652     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)80003-3     Document Type: Article

References (64)

1. Després J.P. Abdominal obesity: The most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl. 8 Suppl B (2006) B4-B12
2. National Center for Health Statistics. Health, United States, 2006 With Chartbook on Trends in the Health of Americans. Hyattsville, Md (2006). http://www.cdc.gov/nchs/data/hus/hus06.pdf Accessed January 26, 2009
3. World Health Organization. Obesity and overweight. Fact Sheet No. 311 (September 2006). http://www.who.int/mediacentre/factsheets/fs311/en/index.html Accessed January 13, 2009
4. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122 (1995) 481-486
5. Carey V.J., Walters E.E., Colditz G.A., et al. Body fat distribution and risk of non-insulin-dependent diabetes melli-tus in women. The Nurses' Health Study. Am J Epidemiol. 145 (1997) 614-619
6. Rexrode K.M., Carey V.J., Hennekens C.H., et al. Abdominal adiposity and coronary heart disease in women. JAMA. 280 (1998) 1843-1848
7. Dagenais G.R., Yi Q., Mann J.F., et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J. 149 (2005) 54-60
8. Calabrò P., Limongelli G., Pacileo G., et al. The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med (Hagerstown). 9 (2008) 450-460
9. Qureshi K., and Abrams G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 13 (2007) 3540-3553
10. Lebovitz H.E. Type 2 diabetes: An overview. Clin Chem. 45 (1999) 1339-1345
11. Banerji M.A., Lebowitz J., Chaiken R.L., et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 273 (1997) E425-E432
12. Després J.P., Lemieux I., Bergeron J., et al. Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk [published correction appears in Arterioscler Thromb Vasc Biol. 2008;28:e151]. Arterioscler Thromb Vasc Biol. 28 (2008) 1039-1049
13. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet. 365 (2005) 1415-1428
14. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J Clin Invest. 106 (2000) 473-481
15. Jensen M.D., Caruso M., Heiling V., and Miles J.M. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 38 (1989) 1595-1601
16. Schindler C. The metabolic syndrome as an endocrine disease: Is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?. Ther Adv Cardiovasc Dis. 1 (2007) 7-26
17. Carr M.C., and Brunzell J.D. Abdominal obesity and dyslipi-demia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 89 (2004) 2601-2607
18. Ginsberg H.N., Zhang Y.L., and Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 36 (2005) 232-240
19. Barnett A.H. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Diab Vasc Dis Res. 5 (2008) 9-14
20. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 112 (2003) 1796-1808
21. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by gluco-corticoid. J Clin Endocrinol Metab. 83 (1998) 847-850
22. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 271 (1996) 665-668
23. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science. 259 (1993) 87-91
24. Feingold K.R., Doerrler W., Dinarello C.A., et al. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130 (1992) 10-16
25. Lau D.C., Dhillon B., Yan H., et al. Adipokines: Molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 288 (2005) H2031-H2041
26. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation. 100 (1999) 2473-2476
27. Nishimura S., Manabe I., Nagasaki M., et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest. 118 (2008) 710-721
28. Fan J., and Watanabe T. Inflammatory reactions in the pa-thogenesis of atherosclerosis. J Atheroscler Thromb. 10 (2003) 63-71
29. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 17 (2006) 4-12
30. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101 (2000) 1767-1772
31. Kern P.A., Ranganathan S., Li C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 280 (2001) E745-E751
32. Senn J.J., Klover P.J., Nowak I.A., and Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002) 3391-3399
33. Spranger J., Kroke A., Möhlig M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52 (2003) 812-817
34. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 8 (2002) 1288-1295
35. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 26 (2005) 439-451
36. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
37. Ahima R.S. Adipose tissue as an endocrine organ. Obesity (Silver Springs) 14 Suppl 5 (2006) 242S-249S
38. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
39. Bruun J.M., Lihn A.S., Verdich C., et al. Regulation of adi-ponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 (2003) E527-E533
40. Tilg H., and Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 14 (2008) 222-231
41. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
42. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
43. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
44. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 291 (2004) 1730-1737
45. Ahima R.S., and Flier J.S. Leptin. Annu Rev Physiol 62 (2000) 413-437
46. Lefebvre A.M., Laville M., Vega N., et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47 (1998) 98-103
47. Leshan R.L., Björnholm M., Münzberg H., and Meyers Jr. M.G. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Springs) 14 Suppl 5 (2006) 208S-212S
48. Déspres J.P., Poirier P., Bergeron J., et al. From individual risk factors and the metabolic syndrome to global metabolic risk. Eur Heart J Suppl 10 Suppl B (2008) B24-B33
49. Minokoshi Y., Kim Y.B., Peroni O.D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 (2002) 339-343
50. Kamohara S., Burcelin R., Halaas J.L., et al. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389 (1997) 374-377
51. Cooke J.P., and Oka R.K. Does leptin cause vascular disease?. Circulation 106 (2002) 1904-1905
52. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resis-tin links obesity to diabetes. Nature 409 (2001) 307-312
53. Kusminski C.M., Mc Ternan P.G., and Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 109 (2005) 243-256
54. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction [published correction appears in Circulation. 2004;109:2254]. Circulation 108 (2003) 736-740
55. Loskutoff D.J., and Samad F. The adipocyte and hemostatic balance in obesity: Studies of PAI-1. Arterioscler Thromb Vasc Biol 18 (1998) 1-6
56. Juhan-Vague I., and Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 78 (1997) 656-660
57. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342 (2000) 1792-1801
58. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology 144 (2003) 2195-2200
59. Juhan-Vague I., Alessi M.C., and Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non- insulin-dependent diabetes mellitus. Ann Med. 28 (1996) 371-380
60. Kushner R.F., and Roth J.L. Assessment of the obese patient. Endocrinol Metab Clin North Am. 32 (2003) 915-933
61. Stafford R.S., Farhat J.H., Misra B., and Schoenfeld D.A. National patterns of physician activities related to obesity management. Arch Fam Med. 9 (2000) 631-638
62. Bardia A., Holtan S.G., Slezak J.M., and Thompson W.G. Diagnosis of obesity by primary care physicians and impact on obesity management. Mayo Clin Proc. 82 (2007) 927-932
63. Klein S., Allison D.B., Heymsfield S.B., et al., the Association for Weight Management and Obesity Prevention, NAASO, Obesity Society, American Society for Nutrition, American Diabetes Association. Waist circumference and cardiometabolic risk. A consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO; the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 30 (2007) 1647-1652
64. Pi-Sunyer X., Blackburn G., Brancati F.L., et al., the Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial. Diabetes Care. 30 (2007) 1374-1383